<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="157212">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01053052</url>
  </required_header>
  <id_info>
    <org_study_id>Femasys 300-001</org_study_id>
    <nct_id>NCT01053052</nct_id>
  </id_info>
  <brief_title>Study of FemVue(TM) Sono Tubal Evaluation System for Sonography Evaluation of Fallopian Tubes and Uterus: Method Comparison to HSG</brief_title>
  <official_title>A Comparative Study of Methods for Tubal Patency Determination and Uterine Cavity Evaluation: Sonography With the FemVue(TM) Catheter System vs. Hysterosalpingography (HSG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Femasys Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Femasys Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center prospective comparison of fallopian tubal patency determination and uterine
      evaluation interventions using legally marketed devices for their intended purposes, and
      using each subject as their own control.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Enrollment for this post-market study is on hold while protocol enhancements are considered by
    the sponsor.
  </why_stopped>
  <start_date>January 2010</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concordance of evaluations of fallopian tube patency and intrauterine pathology.</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>subject discomfort assessment</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Fallopian Tube Patency Tests</condition>
  <arm_group>
    <arm_group_label>Sonography with FemVue vs. HSG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FemVue sonography and HSG</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sonography with FemVue, and HSG</intervention_name>
    <arm_group_label>Sonography with FemVue vs. HSG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Non-pregnant women between the ages of 18 and 45 who desire to know the patency status of
        the fallopian tubes and if the uterine cavity is free of pathology who have:

          -  Been attempting conception for 6 months or

          -  A history of PID (including the conditions listed below) or

               -  Chlamydia

               -  Gonorrhea

               -  Endometriosis

          -  A history of pelvic surgery or

          -  Advanced maternal age (â‰¥ 35) And

          -  Negative test for Gonorrhea/Chlamydia or prophylactic antibiotic treatment

          -  Without current bi-lateral tubal sterilization

          -  Signed Informed Consent

        Exclusion Criteria:

        Uterine anomaly or lesion(s) preventing catheter placement for either the FemVue or HSG
        procedure(as identified and documented by TVUS Screening procedure or the uterine cavity
        evaluation during the FemVue procedure or any previous diagnostic procedure)

          -  obstructing access to uterine cornu

          -  distorting fundus at the midline region
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Anna Parsons, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida, Dept. of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Women's Health Research</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Research Institute of Palm Beach</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtiy of South Florida, Dept. of Obstetrics and Gynecology</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Palm Beach Center for Reproductive Medicine</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Women's Research Institute, Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reproductive Biology Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Advanced IVF Institute</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <lastchanged_date>October 18, 2010</lastchanged_date>
  <firstreceived_date>January 18, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Sponsor Contact: Marc Finch, Vice President, Clinical and Physician Affairs</name_title>
    <organization>Femasys Inc</organization>
  </responsible_party>
  <keyword>Patency Tests, Fallopian Tubes</keyword>
  <keyword>Hysterosalpingography</keyword>
  <keyword>Sonography, Medical</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
